Pharmaceuticals China

China ADHD Drugs Market Analysis, 2024–2034

China ADHD Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Type, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

China · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.36 Bn Estimated value
Estimate 2025 $1.47 Bn 7.3% of the global market
Projected 2034 $2.89 Bn 96.6% Adds $1.42 Bn over 9 forecast years
CAGR 2025–2034 7.8% Faster than 28% of 180 Pharmaceuticals markets here
Key players 5
  • China is 7.27% of the global market.
  • In APAC, the largest is China (this report) at $1.47 Bn.
  • Fastest growing: India at 8.6% a year.
  • China ranks 1st of 10 by size in APAC.

Market size projection

China

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.42 Bn total, 2026–2034

Year-by-year market size, 2024–2034
ADHD Drugs Market market size by year, China
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.36 Bn — —
2025 (base) $1.47 Bn +$106.3 Mn —
2026 (forecast) $1.58 Bn +$114.6 Mn +7.8%
2027 (forecast) $1.71 Bn +$123.5 Mn +16.2%
2028 (forecast) $1.84 Bn +$133.2 Mn +25.3%
2029 (forecast) $1.98 Bn +$143.6 Mn +35%
2030 (forecast) $2.14 Bn +$154.8 Mn +45.6%
2031 (forecast) $2.31 Bn +$166.8 Mn +56.9%
2032 (forecast) $2.49 Bn +$179.9 Mn +69.2%
2033 (forecast) $2.68 Bn +$193.9 Mn +82.4%
2034 (forecast) $2.89 Bn +$209.0 Mn +96.6%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $20.22 Bn
  2. North America $10.94 Bn
  3. US $7.91 Bn
  4. APAC $4.77 Bn
  5. Europe $3.91 Bn
  6. Canada $1.63 Bn
  7. China (this report) $1.47 Bn
  8. Japan $1.42 Bn
  9. Latin America $958.3 Mn
  10. Middle East $779.6 Mn
  11. Germany $640.2 Mn
  12. Brazil $567.3 Mn
  13. France $516.4 Mn
  14. Italy $493.5 Mn
  15. UK $454.8 Mn
  16. Ecuador $424.6 Mn
  17. Spain $397.3 Mn
  18. India $423.4 Mn
  19. Saudi Arabia $357.4 Mn
  20. Mexico $339.8 Mn
  21. Africa $295.0 Mn
  22. Australia $249.4 Mn
  23. New Zealand $228.5 Mn
  24. Russia $211.1 Mn
  25. South Africa $151.2 Mn
  26. UAE $112.5 Mn
  27. Egypt $57.9 Mn
  28. Philippines $50.5 Mn
  29. Hong Kong $33.7 Mn
  30. Malaysia $28.1 Mn
  31. Singapore $23.2 Mn
  32. Thailand $22.5 Mn
  33. Kenya $12.7 Mn

The China ADHD Drugs Market Analysis Executive Summary

ADHD drugs treat attention deficit hyperactivity disorder in children and adults with stimulant and non-stimulant medicines.

Key segments of the ADHD Drugs market include drug type (Stimulants and Non-Stimulants) and age (Children, Adolescents and Adults).

China ADHD Drugs Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the ADHD Drugs market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the ADHD Drugs market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the ADHD Drugs market.

Competitive Landscape for ADHD Drugs Market in China

The ADHD Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for ADHD Drugs Market in China

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for ADHD Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in China.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in ADHD Drugs right now, from free public sources.

Clinical trials

13 active trials in China

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Otsuka Holdings Co Ltd 4 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Supernus Pharmaceuticals 2 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Axsome Therapeutics 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 40 papers since 2021 (worldwide)

  1. AD-Smart: Alzheimer's trial will test diabetes and ADHD drugs on patients. BMJ (Clinical research ed.), 2026
  2. Regional Variation in ADHD Treatment and Diagnosis Among Children and Adolescents in Denmark. Basic & clinical pharmacology & toxicology, 2026
  3. Detrimental effects of atomoxetine on visual signal detection in rats: comparison with ADHD psychomotor stimulant drugs. Psychopharmacology, 2026
  4. The influence of existing interventions on sleep of youth with attention-deficit/hyperactivity disorder: A meta-analysis of randomized controlled trials. Sleep medicine reviews, 2026
  5. Prescribing trends and spontaneous reporting patterns of adverse drug reactions of ADHD medications in children and adolescents in germany: A retrospective analysis (2013-2022). European child & adolescent psychiatry, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

ADHD Drugs in context

China compared

  • Health spending per person: 763 US$ per person (2023). World: 1,317 US$ per person (2023). 5th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 3.11 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 3rd highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 14.9% of people (2025). World: 10.4% of people (2025). 6th highest of the 16 countries we cover in APAC.[3]

Questions, answered with public data

How many clinical trials on ADHD Drugs are running in China?
13 studies are recruiting, active or about to start in China.[4]
How much research is published on ADHD Drugs?
PubMed lists 40 papers added since January 2021 that match this market, worldwide.[5]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.

[5] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about ADHD Drugs in China? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Adaptogens: Ancient Herbs, Modern Market170 WHO Member States report the use of traditional medicine. Adaptogens like ashwagandha, rhodiola and… Stress and Mood Supplements: Ashwagandha and BeyondDepression and anxiety cost the world about US$1 trillion a year. Ashwagandha has some evidence for stress… Antidepressants: Demand, Access and New ApproachesAbout 322 million people live with depression. Treatment works, but most people still do not get it.
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in China

See all
Same topic, other categories

Related on mental health

See the topic